Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2005-06-21
2005-06-21
Andres, Janet (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S085100, C424S085600, C424S085700, C530S351000, C514S052000
Reexamination Certificate
active
06908611
ABSTRACT:
Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compound in combination with an interferon compound. Vitamin B12 compounds are administered separately, simultaneously or in combination with interferon compounds to provide an enhanced therapeutic effect for treating viral, proliferative and inflammatory diseases.
REFERENCES:
patent: 5565558 (1996-10-01), McCully
patent: 5574018 (1996-11-01), Habberfield et al.
patent: 5716941 (1998-02-01), Rabinoff
patent: 5716946 (1998-02-01), DeLuca et al.
patent: 5837822 (1998-11-01), Gallatin et al.
patent: 5846526 (1998-12-01), Cummins
patent: 5858980 (1999-01-01), Weiner et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5948764 (1999-09-01), Guar et al.
patent: 5958409 (1999-09-01), Turk et al.
patent: 6036957 (2000-03-01), Weiner et al.
patent: 6121249 (2000-09-01), Weissman et al.
patent: 6143866 (2000-11-01), Brewer et al.
patent: 6184223 (2001-02-01), Kahn et al.
patent: 6752986 (2004-06-01), Bauer et al.
patent: WO 98/45327 (1998-10-01), None
patent: WO 99/13904 (1999-03-01), None
patent: WO 99/16791 (1999-04-01), None
patent: WO 01/12170 (2001-02-01), None
patent: WO 01/28592 (2001-04-01), None
Johnson et al., Scientific American, May, 1994, pp. 68-75.
Iigo Masaaki et al., “Markedly induced asialoGM1+CD8+ T cell production and enhancement of antimetastatic activity by interferon beta with folic or folinic acid”, XP002227203 abstract, Cancer Immunology Immunotherapy, vol. 44, No. 2, 1997, pp. 65-69, ISSN: 0340-7004.
R. Medenica et al., “Vitamin B-12, A Positive Stimulator of Interferon Activity”, Cancer Immuno-Biology Laboratory and Adolph Coors Clinic of Immunoregulation, Hilton Head Island, SC, abstract; 1995.
Francisco Hernandez et al., “Interferon Alpha-2B and Hydroxocobalamine in Epidemic Neuropathy,” Biotechnologia Aplicada, vol. 12, No. 3, 1995, pp. 191-192.
Database Biosis 'Online!, Biosciences Information Service, Philadelphia, PA, US; 1982, Myasischeva N V et al., “Anti Tumor Efficiency of Methotrexate in Combination With Cobalamin Derivatives”, Database accession No. PREV198477036851, XP002214761, abstract & Eksperimental'Naya Onkologiya, vol. 4, No. 5, 1982, pp. 29-33, ISSN: 0204-3564.
Database Biosis 'Online! Biosciences Information Service, Philadelphia, PA, US; 2000; Pinson Patrick R et al., “Synthesis, protein binding, and cellular uptake of doxorubicin-cobalamin bioconjugates.” Database accession No. PREV200000222560; XP002157413; abstract & Abstracts of Papers American Chemical Society, vol. 219, No. 1-2, p. MEDI 82 219thMeeting of the American Chemical Society; San Francisco, California USA; Mar. 26-30, 2000; ISSN 0065-7727.
Jun-ichi Kira et al., “Vitamine B12 Metabolism and Massive-Dose Methyl Vitamin B12 Therapy in Japanese Patients with Multiple Sclerosis,” Internal Medicine, Japanese Society of Internal Medicine, Tokyo, Japan, vol. 33, No. 2, Feb. 1, 1994, pp. 82-86, XP 000650481, ISSN: 0918-2918, abstract.
Prisms (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Schlerosis), “Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple schlerosis”, Lancet, vol. 352, No. 9139, Nov. 7, 1998, pp. 1498-1504, XP004265722, ISSN: 0140-6736, abstract.
Amit, et al., “Molecular Pathogenesis of Multiple Sclerosis”,J. Immunol, 100:252-259, (1999).
Barron, K., et al., “Multiple Sclerosis”, Rakel, R., Ed. 1995, Conn's Current Gherapy, WB Saunders Company, USA, pp. 732-734.
Brod, SA, et al., “Combination Therapy will Glatiramer Acetate Copolymer-1 and Type I Interferon (interferon-alpha) Does Not Improve Experimental Autoimmune Encephalomyelitis”,Annals of Neurology,47(1), pp. 127-131 (2000).
Cabrera-Gomez, et al., Alpha Interferon in the Treatment of Multiple Sclerosis. Update and Experience in Cuba,Rev. Neuro,28:849-858, (1999).
Cao, et al., “Inhibition of Experimental Allergic Encephalomyelitis in the Lewis Rat by Paclitaxel”,J. Neuroummunol.,108:103-111, (2000).
Chofflon, et al., “Recombinant Human Interferon Beta In Relapsing-Remitting Multiple Sclerosis: A Review of the Major Clinical Trials”,European J. Neur.,7:369, (2000).
Chou, et al., “Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors”,Advances in Enzyme Regulation,vol. 22, pp. 27-55 (1984).
Deisenhammer, et al., “Bioavailability of Interferon-Beta-1B in MS Patients with without Neutralizing Antibodies”,Neurology,52(6), pp. 1239-1243 (1999).
Durelli, et al., “Chronic Systemic High-Dose Recombinant Interferon Alfa-2a Reduces Exacerbation Rate, MRI Signs of Disease Activity and Lymphocyte Interferon Gamma Production in Relapsing-Remitting Multiple Sclerosis”,Neuro,44 (3 Pt 1): 406-413, (1994).
Fine, et al., “A Phase I Trial of a New Recombinant Human Beta-Interferon (BF9015) For the Treatment of Patients with Recurrent Gliomas”,Clinical Cancer Research,3(3), pp. 1-7 (1997).
Hall, et al., “Hydroxycabalamin/Sodium Thiosulfate as a Cyanide Antidote”,J. of Emergency Medicine,5(2), pp. 115-121 (1987).
Ide, H. et al., “Clinical Usefulness of Intrathecal Injection of Methylcobalamin in Patients with Diabetic Neuropathy”,Clin. Ther.,9:183-187, (1987).
Johnson, et al., “Copolymer 1 Reductes Relapse Rate and Improves Disability in Relapsing-Remitting Multiple Sclerosis: Results of Phase III Mulicenter, Double-Blind, Placebo-Controlled Trial”,Neuro,45:1268-1276, (1995).
Johnson, et al., “Extended use of Glatiramer Acetate (Copaxone) is Well Tolerated and Maintains Its Clinical Effect on Multiple Sclerosis Relapse Rate and Degree of Disability”,Neuro,50:701-708, (1998).
Lott, et al., “Vitamin B12 and Hepatitis C: Molecular Biology and Human Pathology”,Mol. Biol. and Human Path.,Proceedings of National Academy of Sciences, 98(9), pp. 4916-4921 (2001).
Mastronardi, et al., “Demyelination in a Transgenic Mouse: A Model for Multiple Sclerosis”,J. Neuro. Res.,36:315-324, (1993).
Mattner, et al., “Inhibition of Th1 Development and Treatment of Chronic-Relapsing Experimental Allergic Encephalomyelitis by a Non-Dihydroxyvitamin D3”,European J. Immunol.,30:498-508, (2000).
Miller, et al., “Magnetic Resonance In Monitoring the Treatment of Multiple Sclerosis”,Ann. Neurol.,36:Supp:S91-4, (1994).
Myhr, et al., Interferon-alpha2a Reduces MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis: Norwegian Study Group on Interferon-alpha in Multiple Sclerosis,Neuro,23:52(5):1049-1056, (1999).
Nataf, et al., “Dihydroxyvitamin D3 Exerts Regional Effects in the Central Nervous System During Experimental Allergic Encephalomyelitis”,J. Neuro Exp. Neuro,55:904-914, (1996).
Nishizawa, et al., “Effects of Methylcobalamin on the Proliferation of Androgen-Sensitive or Estrogen-Sensitive Malignant Cells in Culture and In Vivo”,International J. of Vitamin Nutrition Research,67(3), pp. 164-170 (1997).
Norvedt, et al., “Type I Interferons and the Quality of Life of Multiple Sclerosis Patients. Results from a Clinical Trial on Interferon alfa-2a”,Multiple Scler.,5:317-322, (1999).
O'Connor, et al., “A Phase 1 Study of Micellar Paclitaxel in the Treatment of Secondary Progressive Multiple Sclerosis”,Ann. Neurol,46:470, (1999).
Polman, et al., “Drug Treatment of Multiple Sclerosis”,BMJ,321:490-494, (2000).
Pouly, et al., “Multiple Sclerosis and the Central Nervous System Demyelination”,J. Autoimmu.,13:297-306, (1999).
Poydock, et al., “Inhibiting Effect of Vitamins C and B12 on the Mitotic Activity of Ascites Tumors”,Experimental and Cellular Biology,vol. 47, pp. 210-217 (1979).
Poydock, et al.
Cruz Tony
Pastrak Aleksandra
Andres Janet
Fish & Richardson P.C.
Transition Therapeutics Inc.
LandOfFree
Combination therapies using vitamin B12 and interferon for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapies using vitamin B12 and interferon for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapies using vitamin B12 and interferon for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3510196